echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > FDA approves Roche Amvetin and chemotherapy for treatment after initial surgical removal in women with advanced ovarian cancer

    FDA approves Roche Amvetin and chemotherapy for treatment after initial surgical removal in women with advanced ovarian cancer

    • Last Update: 2020-06-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    recently, the U.SFood andDrug(
    FDA() approved Roche's Avastin (generic name: bevacizumab, bevamono) and chemotherapy (caplatinum y sequoia) after the combination of treatment to continue the Avastin monotherapy model, for advanced stage (stage III or IV) ovarian cancer patients after the first surgery after surgerya monoclonal antibody drug that specifically binds and inhibits the biological effects of vascular endothelial growth factors (VEGF)VEGF is a key driver of tumor angiogenesis, and angiogenesis is needed for tumor growth and diffusion (metastasis)Avastin's precise way of working allows it to be effectively combined with chemotherapy and other forms of anti-cancer treatmentAvastin inhibits tumor growth, prolongs survival, and has limited effect on chemotherapy side effectsthe approval of the relevant research, based on data from the key Phase III clinical study GOG-0218the study was a multicenter, randomized, double-blind, placebo-controlled study conducted in 1,873 previously untreated women with stage III or STAGE IV epithelial ovary, fallopian tubes, or primary peritoneal cancer, who had undergone surgery to remove the tumor as much as possibleIn the study, patients were randomly assigned to three treatment groups: chemotherapy group (caplatinum and yew alcohol), Avastin (15mg/kg) and chemotherapy combined with chemotherapy after receiving a placebo treatment group, Avastin (15 mg/kg) and chemotherapy after combined treatment continued to receive Avastin single-drug treatment group, a total of 22 coursesThe primary endpoint of thestudy was the progressionless lifetime (PFS) assessed by the researchers, and the secondary endpoint scored including total survival (OS)data showed that Avastin continued to receive a significant length of PFS in the Avastin monotherapy group (median PFS: 18.2 months vs 12.0 months, 95% CI: 0.52-0.75, p 0.0001) after combining with chemotherapy This PFS benefit is achieved using fixed duration therapy (a total of 22 courses of Avastin) currently, Avastin has become an important pillar of clinical lygo antiangiogenic therapy, with more than 2.7 million patients worldwide receiving Avastin treatment to date , Roche is currently conducting a large clinical project investigating the potential of Avastin to treat more than 50 types of tumors
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.